Antimicrobial-modified vascular catheters

Biomaterials Associated Infection: Immunological Aspects and Antimicrobial Strategies

Volumn 9781461410317, Issue , 2013, Pages 485-503

  Darouiche, Rabih O ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; MICROORGANISMS;

BACTERIAL COLONIZATION; CATHETER SURFACE; COLONISATION; CONTROL MEASURES; INFECTION CONTROL; MEDICAL CENTER; MODERN HEALTH CARE; PATIENT CARE; SURFACE DURABILITY; SURFACE-MODIFICATION;

CATHETERS;

EID: 84907842580     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1031-7_19     Document Type: Chapter

References (102)

1. O?Grady NP, Alexander M, Burns LA, et al. Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52:1087-99.
2. Demetriades D, May A, Gamble H. When does a Centers for Disease Control and Prevention recommendation become standard of care? Perhaps in the courtroom. American College of Surgeons mock trial: line sepsis liability. J Am Coll Surg. 2008;206:370-5.
3. McGee D, Gould M. Preventing complications of central venous catheterization. N Engl J Med. 2003;348:1123-33.
4. Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized, controlled trial. Ann Surg. 2005;242:193-200.
5. Cicalini S, Palmieri F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care. 2004;8:157-62.
6. Donelli G, Francolini I. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review. J Chemother. 2001;13:595-606.
7. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132: 391-402.
8. Warren DK, Quadir WW, Hollenbeak CS, et al. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006;34:2084-9.
9. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598-601.
10. Heiselman D. Nosocomial bloodstream infections in the critically ill [Letter]. JAMA. 1994; 272: 1819-20.
11. Pittet D, Wenzel RP. Nosocomial bloodstream infections in the critically ill [Letter]. JAMA. 1994;272:1820-1.
12. Dimick JB, Pelz RK, Consunji R, et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136:229-34.
13. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis. 2001;33:1567-72.
14. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus . N Engl J Med. 1999;340:493-501.
15. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999;340:517-23.
16. Raad II, Luna M, Khalil SM, Costerton JW, Lam C, Bodey GP. The relationship between the thombotic and infectious complications of central venous catheters. JAMA. 1994;271: 1014-6.
17. Darouiche RO, Landon GC, Patti JM, et al. Role of Staphylococcus aureus surface adhesions in orthopaedic device infections. J Med Microbiol. 1997;46:75-9.
18. Virden CP, Dobke MP, Stein P, Parsons CJ, Frank DH. Subclinical infection of the silicone breast implant surface as a possible cause of capsular contracture. Aesthetic Plast Surg. 1992;16:173-9.
19. Leung JW, Liu YL, Desta T, Libby E, Inciardi JF, Lam K. Is there a synergistic effect between mixed bacterial infection in bio film formation in biliary stents? Gastrointest Endosc. 1998;48:250-7.
20. Esposito M, Hirsch J, Lekholm U, Thomsen P. Differential diagnosis and treatment strategies for biologic complications and failing oral implants: a review of the literature. Int J Oral Maxillofac Implants. 1999;14:473-90.
21. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneoulsy inserted, non-cuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore). 2002;81:466-79.
22. Maki DG, Cobb L, Garman JK, et al. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med. 1988;85:307-14.
23. Salzman MB, Isenberg HD, Shapiro JF, et al. A prospective study of the catheter hub as the portal of entry for organisms causing catheter-related sepsis in neonates. J Infect Dis. 1993;167:487-90.
24. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis. 1992;15:197-208.
25. Costerton JW, Stewart PS, Greenberg EP. Bacterial bio films: a common cause of persistent infections. Science. 1999;284:1318-22.
26. Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad II, Musher DM. Vancomycin penetration into bio film covering infected prostheses and effect on bacteria. J Infect Dis. 1994;170:720-3.
27. Kumon H, Tomochika K, Matunaga T, et al. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol. 1994;38:615-9.
28. Darouiche RO. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis. 1999;29:1371-7.
29. Zaat SAJ, Broekhuizen CAN, Riool M. Future Microbiol. 2010;5:1149-51.
30. Thornton J, Todd NJ, Webster NR. Central venous line sepsis in the intensive care unit: a study comparing antibiotic coated catheters with plain catheters. Anaesthesia. 1996;51:1018-20.
31. Bassetti S, Hu J, D?Agostino Jr RB, Sherertz RJ. In vitro zones of inhibition of vascular catheters predict efficacy in preventing catheter infection with Staphylococcus aureus in vivo. Eur J Clin Microbiol Infect Dis. 2000;19:612-7.
32. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother. 1995;39:2397-400.
33. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173:418-24.
34. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1-8.
35. Sherertz RJ, Heard SO, Raad II, et al. Gamma radiation-sterilized, triple-lumen catheters with a low concentration of chlorhexidine were not efficacious at preventing catheter infections in intensive care unit patients. Antimicrob Agents Chemother. 1996;40:1995-7.
36. Jansen B, Rinck M, Wolbring P, Strohmeier A, Jahns T. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomat App. 1994;9: 55-70.
37. Kampf G, Dietze B, Grobe-Siestrup C, Wendt C, Martiny H. Microbicidal activity of a new silver-containing polymer, SPI-ARGENT II. Antimicrob Agents Chemother. 1998;42:2440-2.
38. Gilbert JA, Cooper RC, Puryear HA, et al. A swine model for the evaluation of efficacy of anti-microbial catheter coatings. J Biomater Sci Polym Ed. 1998;9:931-42.
39. Goldschmidt H, Hahn U, Satwender HJ, et al. Prevention of catheter-related infections by silvercoated central venous catheters in oncological patients. Zentralbl Bakteriol. 1995;283:215-23.
40. Bach A, Eberhardt H, Frick A, et al. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Crit Care Med. 1999;27:515-21.
41. Dunser MW, Mayr AJ, Hinterberger G, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesth Analg. 2005;101:1778-84.
42. Kalfon P, de Vaumus C, Samba D, et al. Comparison of silver-impregnated with standard multilumen central venous catheters in critically ill patients. Crit Care Med. 2007;35:1032-9.
43. Trerotola S, Johnson M, Shah H, et al. Tunneled hemodialysis catheters: use of a silvercoated catheter for prevention of infection-A randomized study. Radiology. 1998;207:491-6.
44. Schierholz JM, Wachol-Drewek Z, Lucas LJ, Pulverer G. Activity of silver ions in different media. Zentralbl Bakteriol. 1998;287:411-20.
45. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis. 1993;167:920-4.
46. Moss HA, Se T, Faroqui MH, et al. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur J Anesthesiol. 2000;17:680-7.
47. Jaeger K, Osthaus A, Heine J, et al. Efficacy of a benzalkonium chloride-impregnated central venous catheter to prevent catheter-associated infection in cancer patients. Eur J Chemother. 2001;47:50-5.
48. Kamal GD, Pfaller MA, Rempe LE, et al. Reduced intravascular catheter infection by antibiotic bonding. JAMA. 1991;265:2364-8.
49. Thornton J, Todd NJ, Webster NR. Central venous line sepsis in the intensive care unit: a study comparing antibiotic coated catheters with plain catheters. Anesthesia. 1996;51:1018-20.
50. Ranucci M, Isgro G, Giomarelli PP, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med. 2003;31:52-9.
51. Fraenkel D, Rickard C, Thomas P, Faogali J, George N, Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med. 2006;34:668-75.
52. Schierholz JM, Fleck C, Beuth J, Pulverer G. The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity. J Antimicrob Chemother. 2000;46:45-50.
53. Yucel N, Lefering R, Meagele M, et al. Reduced colonization and infection with miconazolerifampicin modi fied central venous catheters: a randomized controlled clinical trial. J Antimicrob Chemother. 2004;54:1109-15.
54. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg. 1996;62:641-6.
55. Osma S, Kahveci SF, Kaya FN, et al. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit. J Hosp Infect. 2006;62:156-62.
56. Logghe C, Van Ossel C, D?Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect. 1997;37:145-56.
57. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luk KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn Microbiol Infect Dis. 2000;38:1-5.
58. Carrasco MN, Bueno A, de las Cuevas C, et al. Evaluation of a triple-lumen central venous heparin heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Med. 2004;30:633-8.
59. Heard SO, Wagle M, Vijayakumar E, et al. The influence of triple-lumen central venous catheters coated with chlorhexidine/silversulfadiazine on the incidence of catheter-related bacteremia: a randomized, controlled clinical trial. Arch Intern Med. 1998;158:81-7.
60. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized clinical trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg. 1997;132:1348-51.
61. Brun-Buisson C, Doyon F, Sollet LP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver-sulfadiazine-coated catheters: a randomized controlled trial. Intensive care Med. 2004;30:837-43.
62. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled study. Ann Intern Med. 1997;127:257-66.
63. Jeager K, Zenz S, Juttner B, et al. Reduction of catheter-related infections in neutropenic patients: a prospective controlled trial using chlorhexidine and silver sulfadiazine-impregnated central venous catheter. Ann Hematol. 2005;84:258-62.
64. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med. 2005;143:570-80.
65. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA. 1999;281:261-7.
66. Hockenhull JC, Dwan KM, Smith GW, et al. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit Care Med. 2009;37:702-12.
67. Ramritu P, Halton K, Colligan P, et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am J Infect Control. 2008;36:104-17.
68. Bassetti S, Hu J, D?Agastino Jr et al. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infection. Antimicrob Agents Chemother. 2001;45:1535-8
69. Raad I, Hana H. Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections. Support Care Cancer. 1999;7:386-90.
70. Walz JM, Avelar RL, Longtine KJ, et al. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-flurouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care Med. 2010;38:2095-102.
71. Darouiche RO, Raad II, Bodey GP, Musher DM. Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin. Int J Antimicrob Agents. 1995;6:31-6.
72. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173:418-24.
73. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in bio film. Antimicrob Agents Chemother. 2007;51:1656-60.
74. Widmer AF, Frei R, Rajacic Z, et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis. 1990;162:96-102.
75. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med. 1997;127:267-74.
76. Leon C, Ruiz-Santana S, Rello J, et al. Bene fits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med. 2004;30:1891-9.
77. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1-8.
78. Marick PE, Abraham G, Careau P, Varon J, Fromm Jr RE. The ex vivo antibacterial activity and colonization rate of two antimicrobial-coated central venous catheters. Crit Care Med. 1999;27: 1128-31.
79. Hanna H, Benjamin R, Chatzinikolau I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective, randomized clinical trial. J Clin Oncol. 2004; 22:3163-71.
80. Chatzinikolau I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular-catheter related infections: a prospective, randomized study. Am J Med. 2003;115:352-7.
81. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolau I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;59:359-69.
82. Pai MP, Pendland SL, Danziger LH. Antimicrobial-coated/bonded and -impregnated intravascular catheters. Ann Pharmacother. 2001;35:1255-63.
83. Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis. 2008;21:235-45.
84. Sampath LA, Tambe SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol. 2001;22:640-6.
85. Aslam S, Darouiche RO. Prolonged bacterial exposure to minocycline/rifampicin-impregnated vascular catheters does not affect antimicrobial activity of catheters. J Antimicrob Chemother. 2007;60:148-51.
86. Munson EL, Heard SO, Doern GV. In vitro exposure of bacteria to antimicrobial impregnated-central venous catheters does not directly lead to the emergence of antimicrobial resistance. Chest. 2004;126:1628-35.
87. Chatzinikolaou I, Hanna H, Graviss L, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003;24:961-3.
88. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis. 2003;37:65-72.
89. Crnich CJ, Maki DG. Are antimicrobial-impregnated catheters effective? Don?t throw out the baby with the bathwater. Clin Infect Dis. 2004;38:1287-92.
90. McConnell SA, Gubbins PO, Anaissie EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. Clin Infect Dis. 2004;39:1829-33.
91. Richards MJ, Edwards JR, Culver DH, Gaines RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887-92.
92. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2007;355:2725-32.
93. Warren DK, Zack JE, May field JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest. 2004;126:1612-8.
94. Sherertz RJ, Ely EW, Westbrook DM, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med. 2000;132:641-8.
95. Bijma R, Girbes AR, Klejer DJ, et al. Preventing central venous catheter-related infection in a surgical intensive-care unit. Infect Control Hosp Epidemiol. 1999;20:618-20.
96. O?Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2002;51(RR-10):1-29.
97. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis. 2002;34:1232-42.
98. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis. 2002;34:1362-8.
99. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554-60.
100. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. Chest. 2003;124:275-84.
101. Bouza E, Guembe M, Munoz P. Selection of the vascular catheter: can it minimise the risk of infection. Int J Antimicrob Agents. 2010;36 Suppl 2:S22-5.
102. Raad I, Hana H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis. 2007;7:645-57.